'I think therefore I am': improving cognition.
OBJECTIVE
In the absence of a specific treatment for dementia, the effective management of cognitive symptoms is a clinical priority.


RESULTS
Although some differences have been observed in the profile of cognitive complaints observed in subtypes of dementia, there is increasing recognition of common, interacting neurobiological causes suggesting the need to seek a common treatment applicable to all causes of cognitive deterioration. There also exists increasing interest in intervening at the level of minor cognitive dysfunction by reducing risk factors for subclinical states.


CONCLUSIONS
Pharmacological treatment of cognitive disorder is beneficial but has only temporary benefit for a subgroup of patients. Pharmacogenetics may have an important future role to play in deciding which patients may best benefit from the treatment. Low side effect therapies such as cognitive therapy and acupuncture show some benefits but their utility in combination with pharmacotherapies remains to be demonstrated. Prevention of milder forms of cognitive disorder by controlling risk factors such as hypertension and diabetes may reduce rates of more severe cognitive degeneration. Persons with cognitive dysfunction are commonly excluded from making decisions about the implementation of cognition-enhancing treatments although they wish to do so.
Ritchie
Karen
K
French National Institute of Health and Medical Research (INSERM), Unit E361 Pathologies of the Nervous System, La Colombière Hospital, Montpellier, France. Ritchie@montp.inserm.fr
Portet
Florence
F
D003071:Cognition; D003072:Cognition Disorders / Q000150:complications / Q000523:psychology / Q000628:therapy*; D003657:Decision Making; D003704:Dementia / Q000150:complications* / Q000523:psychology*; D006801:Humans; D007258:Informed Consent / Q000523:psychology; D012307:Risk Factors; D013850:Thinking